Eli Lilly and Company successfully recovered the domain foundayo.moscow from respondent Маргарита Генриховна Зайцева. The panel ruled in favor of transfer after finding the respondent used the domain to operate a fake shop selling unauthorized pharmaceutical products.
Case Snapshot
| Case Number | D2026-3633 |
|---|---|
| Complainant | Eli Lilly and Company |
| Respondent | Маргарита Генриховна Зайцева |
| Disputed Domain | foundayo.moscow |
| Threat Tactic | Fake Stores |
| Decision Date | 2026-09-10 |
| Panelist | Assen Alexiev |
| Outcome | Transfer |
| Official Source | https://www.wipo.int/amc/en/domains/search/text.jsp?case=D2026-3633 |
Facing Unauthorized Domain Registrations or Brand Abuse?
Our domain dispute attorneys represent trademark owners and businesses worldwide before WIPO, Forum (NAF), and CAC. Explore our Domain Name Disputes and Enforcement & Takedowns services, or request a free case evaluation.
Request Case EvaluationOperational Risks and Consumer Safety Concerns in Pharmaceutical Impersonation
The operation of the disputed domain foundayo.moscow illustrates a significant threat to brand integrity and consumer health through the unauthorized distribution of pharmaceutical products. By utilizing the FOUNDAYO trademark to host a Russian-language shop, the respondent created a sophisticated impersonation vector designed to deceive unsuspecting users. This storefront explicitly bypassed regulatory frameworks, offering medication not approved for distribution in the target jurisdiction. The respondent exacerbated these risks by mimicking official branding and product imagery, creating a false perception of affiliation with Eli Lilly and Company. Such unauthorized activities undermine global distribution compliance and expose the complainant to liability for products that lack quality control and verification of origin.
Furthermore, the site presented clear technical indicators of fraudulent activity, including the display of browser-level security warnings regarding the absence of a private, encrypted connection. The complete lack of identifiable business details—such as a verifiable physical address or contact information—further differentiates this site from legitimate pharmaceutical retailers. Beyond the immediate intellectual property infringement, the presence of such sites creates an environment of consumer distrust, as users may inadvertently consume counterfeit or grey-market versions of medication that diverge from established therapeutic standards and official packaging specifications. This case highlights the necessity for proactive domain monitoring to detect and mitigate the impact of rogue digital storefronts operating within regulated sectors.
Legal Analysis: Establishing Infringement and Bad Faith in Pharmaceutical Impersonation
The Panel confirmed that the disputed domain name, foundayo.moscow, is identical or confusingly similar to Eli Lilly and Company’s FOUNDAYO trademark. This finding rested on a direct comparison between the complainant’s established trademark rights and the domain name, fulfilling the standing requirement of the UDRP. Because the trademark is uniquely associated with the complainant’s pharmaceutical product, the panel determined that there was a high likelihood of consumer confusion.
Regarding rights or legitimate interests, the respondent failed to establish any common knowledge of the domain name or a legitimate noncommercial or fair use. The record demonstrated that the respondent was not engaged in a bona fide offering of goods or services, particularly given that the FOUNDAYO product is not legally approved for distribution in the Russian Federation. The absence of verifiable business details, such as a physical address or contact information, further negated any claim of a legitimate commercial presence.
The panel found compelling evidence of bad faith through the respondent’s operation of a fraudulent website. By utilizing the complainant’s trademark and copyrighted product images without authorization, the respondent intentionally sought to attract internet users for commercial gain by misrepresenting an affiliation with Eli Lilly. The respondent’s failure to secure the website—evidenced by browser-level security warnings—underscores the lack of professional legitimacy and the high probability that the site functioned as a vehicle for the unauthorized distribution of pharmaceuticals. Such conduct reflects a clear bad faith intent to exploit the complainant’s reputation for illicit gain.
Strategic Enforcement Against Unauthorized Pharmaceutical Impersonation
The complainant’s strategy was centered on demonstrating the respondent’s bad faith through the lack of transparency on the infringing website. By highlighting that the site at foundayo.moscow failed to provide any business name, physical address, or contact email, Eli Lilly effectively stripped the respondent of any claim to legitimate commercial activity. This absence of verifiable business identity, combined with the unauthorized use of the FOUNDAYO trademark to promote medication not approved for the Russian market, provided the panel with clear evidence that the respondent intended to confuse consumers for commercial gain. Such evidence is essential in UDRP proceedings where the respondent remains anonymous or uncooperative, as it characterizes the domain as a platform for grey market activity rather than a legitimate business.
Furthermore, the complainant’s procedural handling of the language of the proceeding strengthened its position. By proactively requesting that English be the language of the proceeding despite the Russian registration agreement, and by noting the respondent’s failure to contest this request, the complainant ensured the panel could efficiently process the technical evidence. The complainant further bolstered its case by linking the domain’s lack of a private, secure connection—evidenced by browser security warnings—to the broader risk of counterfeit pharmaceutical distribution. This multidimensional approach, which combined trademark rights with evidence of regulatory non-compliance and technical security failures, created a persuasive narrative that convinced the panel the domain was being held in bad faith to exploit the complainant’s reputation.
Practical Recommendations
- Conduct continuous monitoring for unauthorized FOUNDAYO domains and use automated takedown tools for websites lacking verifiable physical business information.
- Submit screenshot evidence of browser security warnings alongside UDRP filings to establish the technical context of fraudulent, non-secure operations.
- Implement a proactive brand protection strategy that includes filing trademark registrations in high-risk jurisdictions even before official product rollouts.
- Leverage the absence of contact details, such as physical addresses and verified business emails, to support claims of bad faith in future UDRP proceedings.
- Prepare for potential language of proceedings disputes in non-English jurisdictions by documenting the international nature of the trademark and the respondent’s intentional targeting of a global audience.
Frequently Asked Questions (FAQ)
Why was the domain ‘foundayo.moscow’ considered confusingly similar to the complainant’s trademark?
The WIPO panel determined that the disputed domain consists entirely of the ‘FOUNDAYO’ mark. Because Eli Lilly holds valid trademark registrations for FOUNDAYO, the inclusion of the identical trademark within the domain name creates a high likelihood of confusion for internet users.
What evidence established that the respondent lacked rights or legitimate interests in the domain?
The panel found that the respondent was not commonly known by the name, did not use the domain for a bona fide offering of goods, and was not making a legitimate noncommercial use. The respondent’s site was found to be an unauthorized pharmaceutical shop selling products not approved for distribution in the target region.
How was bad faith proven in the operation of the fake shop?
Bad faith was demonstrated by the respondent’s unauthorized use of Eli Lilly’s copyrighted product imagery and the intent to commercialize the FOUNDAYO mark without permission. Furthermore, the site’s failure to provide verifiable business contact information and the deliberate mimicking of the complainant’s brand confirm an intentional attempt to attract users for profit.
What is the practical takeaway from this case regarding online pharmaceutical fraud?
The case highlights the risk of ‘fake shops’ using suspicious domains—often flagged by browser security warnings—to distribute counterfeit or grey market medicine. The transfer of ‘foundayo.moscow’ confirms that UDRP proceedings are an effective tactical tool for forcing the removal of fraudulent sites that jeopardize consumer health and brand reputation.
Found a fake shop using your brand?
Unauthorized sites posing as your official storefront can distribute counterfeit goods and damage your reputation. Learn how to identify and pursue legal action against these infringing domains.
This case note is for informational purposes only and is not legal advice.
